Company Active LTD

Company profile

Gendius Limited

UK company 08525197, incorporated on 13 May 2013.

Home - Gendius

Experts in health data Redefining personalised care with innovative solutions using rich metabolic data, enabling healthcare teams to improve patient outcomes. Our partners Creating data driven solutions for good User ExperienceWe include our users throughout each project, ensuring our solutions are optimised specifically to their needs. Health DataUtilising our expertise in metabolic data and methodologies to

Company number
08525197
Incorporated
13 May 2013
Companies House status
Active

Company identity

Founded / incorporated
13 May 2013

Company number 08525197

Verify at Companies House
Legal name
GENDIUS LIMITED
Company type
LTD
Region
Unknown
Registered address
Unknown
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

11 levels 2 ultimate controllers
1
Company Active LTD
Gendius Limited
CRN 08525197
2
Direct controller Active LTD
3
Intermediate controller Active LTD
4
Intermediate controller Active LTD
5
Ultimate controller Active LTD
6
Intermediate controller Active LLP
Barnett Waddingham LLP
CRN OC307678
7
Intermediate controller Active LTD
8
Intermediate controller Active LTD
9
Intermediate controller Active LTD
10
Intermediate controller Active LTD
HGH Midco 3 Limited
CRN 13646017
11
Intermediate controller Active LTD
Hig Finance 2 Limited
CRN 10842605
12
Intermediate controller Active LTD
HGH Finance Limited
CRN 13645436
13
Intermediate controller Active LTD
HGH Midco 2 Limited
CRN 13644440
14
Intermediate controller Active LTD
HGH Midco 1 Limited
CRN 13642978
15
Ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

1 event
13 May
2013

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2017
Funded years
2017, 2023
Age at first award
3 years

Projects

2023 Investment Accelerator

GM Advanced Diagnostics Accelerator

1 Apr 2023 to 31 Mar 2025

Awarded
£167,845
Total cost £239,778

no public description

2017 Collaborative R&D Lead participant

Intellin: A smart platform to reduce the reoccurrence of diabetic foot ulcers

1 May 2017 to 30 Apr 2020

Awarded
£196,979
Total cost £281,398

Diabetic Foot Ulcers (DFUs) are a major worldwide issue, occurring in 15% of diabetes sufferers and 56% of these patients die within 5 years of the first occurrence. The recurrence rate is approximately 50% per annum with current methods and treatment requiring a multidisciplinary assessment (including diabetes specialists, surgeons and podiatrists). Ther...

Product types

Collaborative R&D Investment Accelerator